South Africa’s National Department of Health has confirmed that the country’s supply of antiretroviral medicines remains stable despite two pharmaceutical companies contracted under the current ARV tender entering business rescue. The development affects millions of HIV patients reliant on uninterrupted treatment, particularly those using public health facilities in Gauteng. Health authorities say contingency measures were activated immediately to prevent any disruption to treatment.
According to the department, provinces currently hold sufficient stock of the affected antiretroviral medicines to meet demand for approximately three months, while alternative suppliers increase production to cover any potential shortfalls.
ALSO READ: Book Your Home Affairs Appointment Online – Fast, Easy & Hassle-Free!
What Triggered the Department’s Intervention
The Department of Health said it became aware of the supplier challenges through media reports, followed by direct engagements with the affected companies. Officials then assessed the potential impact on production timelines and national stock levels.
Health authorities moved quickly to activate safeguards built into the ARV tender, which was designed to withstand supplier instability without affecting patient access.
“The ARV tender was deliberately awarded to multiple suppliers as a risk-mitigation strategy to ensure continuity of supply in the event of constraints by any individual supplier,” the department said.
Multiple Supplier Model Activated
South Africa’s ARV procurement model relies on multiple contracted suppliers rather than a single manufacturer. According to the department, this approach allows production volumes to be shifted when one supplier experiences operational or financial difficulties.
Following confirmation that two suppliers had entered business rescue, the department engaged other awarded manufacturers to scale up output and stabilise supply.
Officials said this process began immediately after the supply risks were identified.
Current Stock Levels Across Provinces
Based on national stock monitoring data, the department said provinces collectively hold enough stock of the affected ARVs to cover roughly three months of expected consumption.
Stock levels are being tracked continuously at both national and provincial levels, with additional production orders already placed to ensure buffer supplies remain in place.
Health authorities stressed that no shortages have been reported at public health facilities.
Why ARV Supply Stability Matters
South Africa runs the largest HIV treatment programme in the world, with more than 5.7 million people currently receiving antiretroviral therapy through the public health system.
Any interruption in ARV supply carries serious public health risks, including:
- Treatment interruption
- Increased risk of drug resistance
- Higher HIV-related illness and mortality
The department said these risks were central to the tender’s design and the rapid response once supplier instability emerged.
What the Department Is Saying
Departmental spokesperson Foster Mohale said supplier challenges linked to financial distress were not new and had been anticipated during procurement planning.
According to Mohale, the department has historically maintained a buffer stock to prevent supply disruptions, with newer systems now providing real-time monitoring of consumption and stock levels.
“This approach enables the department to respond swiftly by engaging alternative contracted suppliers where necessary,” Mohale said.
He added that contingency measures were activated at the same time as engagements with the affected companies.
Patients Urged to Continue Treatment as Normal
The department has urged patients to continue collecting their medication as usual, stressing that there is currently no shortage of ARVs at public clinics and hospitals.
“The department understands the consequences of the country running out of ARVs and will never allow this to happen,” Mohale said.
Health officials also cautioned against panic-driven behaviour, such as stockpiling medication, which can unnecessarily strain facility-level supplies.
What This Means for Gauteng Residents
For Gauteng residents, where patient volumes are among the highest in the country, the department’s assurance means HIV treatment services are expected to continue without interruption.
Clinics and hospitals in Johannesburg, Tshwane, and Ekurhuleni rely on tightly managed supply chains to support large numbers of patients. Any disruption would place immediate pressure on facilities already operating at high capacity.
Health authorities say current safeguards are designed to protect patients from supplier-side instability and ensure continuity of care at the facility level.
Frequently Asked Questions
Are ARVs currently out of stock at clinics?
No. The department says there is no ARV shortage at public health facilities.
Why did the suppliers enter business rescue?
The department has not disclosed specific financial details but confirmed the situation is being managed.
How long will the current stock last?
Provinces hold enough stock to meet approximately three months of demand.
Can supplier issues affect future access to treatment?
The department says contingency plans are in place to prevent disruption.
Should patients collect medication earlier than usual?
No. Patients are advised to follow their normal collection schedules.
What Happens Next
The Department of Health says it will continue engaging all contracted ARV suppliers while closely monitoring national and provincial stock levels. Further updates are expected as supplier recovery processes unfold.
Health officials say the situation remains under active management, with patient access to life-saving HIV treatment remaining a national priority.
